Recombinant Human Deoxyhypusine synthase/DHS Protein，His

Deoxyhypusine synthase (DHS) is an essential enzyme that catalyzes the first step in the hypusine biosynthesis pathway, specifically the conversion of the translation factor eIF5A's lysine residue to deoxyhypusine. This post-translational modification is crucial for eIF5A's role in protein synthesis and cellular proliferation. Recent research has highlighted DHS as a potential target for cancer therapy, as its activity is often upregulated in various malignancies, contributing to uncontrolled cell growth. The recombinant production of DHS allows for in-depth structural and functional studies, aiding in the understanding of its enzymatic mechanism and its regulatory processes. Investigating the properties of DHS in a recombinant form not only facilitates the exploration of its interactions with substrates and inhibitors but also supports the development of potent pharmacological agents aimed at modulating its activity. By elucidating the role of DHS in cellular physiology and its implications in disease contexts, researchers aim to harness this knowledge for therapeutic advances, particularly in cancer treatments, where selective inhibition of DHS could potentially lead to diminished tumor growth and improved patient outcomes. The ongoing studies on recombinant DHS underscore its significance in both basic research and drug development, making it a pivotal focus within the fields of biochemistry, molecular biology, and medical science.